4.7 Article

Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?

Journal

PSYCHOLOGICAL MEDICINE
Volume 43, Issue 4, Pages 699-709

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0033291712001675

Keywords

Augmentation; depression; exercise; insomnia; physical activity; sleep

Funding

  1. National Institute for Mental Health [NIMH 1-R01-MH067692-01]
  2. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  3. Agency for Healthcare Research and Quality (AHRQ)
  4. Corcept Therapeutics, Inc.
  5. Cyberonics, Inc.
  6. Merck
  7. NARSAD
  8. NIMH
  9. National Institute on Drug Abuse
  10. Naurex
  11. Novartis
  12. Pharmacia Upjohn
  13. Predix Pharmaceuticals (Epix)
  14. Solvay Pharmaceuticals, Inc.
  15. Targacept
  16. Valient
  17. Abbott Laboratories, Inc.
  18. Abdi Ibrahim
  19. Akzo (Organon Pharmaceuticals Inc.)
  20. Alkermes
  21. Astra-Zeneca
  22. Bristol-Myers Squibb Company
  23. Cephalon, Inc.
  24. Evotec
  25. Fabre Kramer Pharmaceuticals, Inc.
  26. Forest Pharmaceuticals
  27. GlaxoSmithKline
  28. Janssen Pharmaceutica Products
  29. Libby
  30. LP
  31. Johnson Johnson PRD
  32. Eli Lilly Company
  33. Meade Johnson
  34. Medtronic
  35. Neuronetics
  36. Otsuka Pharmaceuticals
  37. Parke-Davis Pharmaceuticals, Inc.
  38. Pfizer Inc.
  39. Sepracor
  40. SHIRE Development
  41. Sierra
  42. Tal Medical/Puretech
  43. Transcept
  44. VantagePoint
  45. Wyeth-Ayerst Laboratories

Ask authors/readers for more resources

Background. Sleep disturbances are persistent residual symptoms following remission of major depressive disorder (MDD) and are associated with an increased risk of MDD recurrence. The purpose of the current study was to examine the effect of exercise augmentation on self-reported sleep quality in participants with non-remitted MDD. Method. Participants were randomized to receive selective serotonin reuptake inhibitor (SSRI) augmentation with one of two doses of exercise : 16 kilocalories per kilogram of body weight per week (KKW) or 4 KKW for 12 weeks. Depressive symptoms were assessed using the clinician-rated Inventory of Depressive Symptomatology (IDS-C). The four sleep-related items on the IDS-C (Sleep Onset Insomnia, Mid-Nocturnal Insomnia, Early Morning Insomnia, and Hypersomnia) were used to assess self-reported sleep quality. Results. Significant decreases in total insomnia (p<0.0001) were observed, along with decreases in sleep onset, mid-nocturnal and early-morning insomnia (p's <0.002). Hypersomnia did not change significantly (p=0.38). Changes in total, mid-nocturnal and early-morning insomnia were independent of changes in depressive symptoms. Higher baseline hypersomnia predicted a greater decrease in depression severity following exercise treatment (p=0.0057). No significant moderating effect of any baseline sleep on change in depression severity was observed. There were no significant differences between exercise treatment groups on total insomnia or any individual sleep item. Conclusions. Exercise augmentation resulted in improvements in self-reported sleep quality in patients with non-remitted MDD. Given the prevalence of insomnia as a residual symptom following MDD treatment and the associated risk of MDD recurrence, exercise augmentation may have an important role in the treatment of MDD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available